Insider txns (12m)
17
Stock / equity
INVA Innoviva, Inc.
- Company
- Innoviva, Inc.
- Security
- Equity
- Size, estimated from filings
- Small cap ($300M – $2B)
- Insiders on record
- 6
- Latest trade on record
- August 20, 2026
INVA (Innoviva, Inc.) has 17 disclosed insider transactions from 5 insiders in the last 12 months (0 open-market buys, 6 sales, about $122K at reported prices) and 0 congressional trades from 0 members of Congress. The most recent disclosure was filed August 24, 2026.
Open-market buys / sales
0 / 6
Congress trades (12m)
0
Distinct filers (12m)
5
Share price
Price and chart by TradingView for Innoviva, Inc.. US share prices here are delayed, not real-time. The trade records on this page come from government filings, not from this chart.
INVA in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
BoughtSold
3 people account for the disclosed buying and selling in INVA over the last 12 months; the most active is Raifeld Pavel with $49K.
Insider holdings over time
Is an insider building or unwinding a position? Shares held directly after each filing.
Raifeld PavelZhen Marianne
Raifeld Pavel reported 284,799 shares held after the latest filing, against 285,936 at the first on record.
Insiders trading INVA
Everyone who filed a Form 4 for this ticker, by number of rows on record. "Bought" and "sold" count open-market purchases (code P) and sales only; awards, option exercises and shares withheld for tax are in the row count but not in those two columns.
| Insider | Role | Rows | Bought | Sold | Value bought | Value sold | Latest |
|---|---|---|---|---|---|---|---|
| Raifeld Pavel | Chief Executive Officer | 5 | 0 | 2 | — | $49K | August 20, 2026 |
| Zhen Marianne | Chief Accounting Officer | 4 | 0 | 2 | — | $49K | August 20, 2026 |
| Basso Stephen | Chief Financial Officer | 3 | 0 | 2 | — | $24K | August 20, 2026 |
| Linden Josephine | Director | 3 | 0 | 0 | — | — | May 18, 2026 |
| DiPaolo Mark | Director | 2 | 0 | 0 | — | — | May 4, 2026 |
| GLAXOSMITHKLINE PLC | Insider | 1 | 0 | 1 | — | $392.1M | May 20, 2021 |
What kind of transactions these are 3 Form 4 codes
| Code | Meaning | Rows | Shares | Value at reported prices |
|---|---|---|---|---|
| A | Grant or award | 11 | 529,804 | — |
| F | Shares withheld for tax | 6 | 5,631 | $122K |
| S | Open-market sale | 1 | 32,005,260 | $392.1M |
What each code means: Form 4 transaction codes.
Insider transactions
| Filer | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Raifeld Pavel | Sell F | August 20, 2026 | August 24, 2026 | 4d | 1,130 | $21 | $24K | Form 4 ↗ | ||
| Basso Stephen | Sell F | August 20, 2026 | August 24, 2026 | 4d | 558 | $21 | $12K | Form 4 ↗ | ||
| Zhen Marianne | Sell F | August 20, 2026 | August 24, 2026 | 4d | 1,127 | $21 | $24K | Form 4 ↗ | ||
| Zhen Marianne | Sell F | May 20, 2026 | May 22, 2026 | 2d | 1,127 | $22 | $25K | Form 4 ↗ | ||
| Raifeld Pavel | Sell F | May 20, 2026 | May 22, 2026 | 2d | 1,130 | $22 | $25K | Form 4 ↗ | ||
| Raifeld Pavel | Other A | May 15, 2026 | May 22, 2026 | 7d | 1,123 | — | — | late | Form 4 ↗ | |
| Basso Stephen | Sell F | May 20, 2026 | May 22, 2026 | 2d | 559 | $22 | $12K | Form 4 ↗ | ||
| Basso Stephen | Other A | May 15, 2026 | May 22, 2026 | 7d | 1,123 | — | — | late | Form 4 ↗ | |
| Linden Josephine | Other A | May 18, 2026 | May 20, 2026 | 2d | 9,166 | — | — | derivative | Form 4 ↗ | |
| Linden Josephine | Other A | May 18, 2026 | May 20, 2026 | 2d | 9,461 | — | — | Form 4 ↗ | ||
| Linden Josephine | Other A | May 18, 2026 | May 20, 2026 | 2d | 5,733 | — | — | Form 4 ↗ | ||
| Zhen Marianne | Other A | May 4, 2026 | May 6, 2026 | 2d | 31,500 | — | — | derivative | Form 4 ↗ | |
| Zhen Marianne | Other A | May 4, 2026 | May 6, 2026 | 2d | 12,766 | — | — | Form 4 ↗ | ||
| Raifeld Pavel | Other A | May 4, 2026 | May 6, 2026 | 2d | 312,500 | — | — | derivative | Form 4 ↗ | |
| Raifeld Pavel | Other A | May 4, 2026 | May 6, 2026 | 2d | 126,646 | — | — | Form 4 ↗ | ||
| DiPaolo Mark | Other A | May 4, 2026 | May 6, 2026 | 2d | 10,000 | — | — | derivative | Form 4 ↗ | |
| DiPaolo Mark | Other A | May 4, 2026 | May 6, 2026 | 2d | 9,786 | — | — | Form 4 ↗ | ||
| GLAXOSMITHKLINE PLC | Sell S | May 20, 2021 | May 24, 2021 | 4d | 32,005,260 | $12 | $392.1M | indirect | Form 4 ↗ |
Congressional trades
No member of Congress has disclosed a trade in this ticker in the filings we have parsed.
Related stocks
Tickers traded by the same people who traded INVA, by number of filers in common. It shows overlap in public filings and nothing else.
- WVE Wave Life Sciences, Inc. 1 filer in common
- BCYC BICYCLE THERAPEUTICS PLC 1 filer in common
- CVRX CVRx, Inc. 1 filer in common
- LYEL Lyell Immunopharma, Inc. 1 filer in common
- DBTX Decibel Therapeutics, Inc. 1 filer in common
- GNCA GENOCEA BIOSCIENCES, INC. 1 filer in common
- TBPH Theravance Biopharma, Inc. 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 11 | 18 | May 24, 2021 | August 24, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insider rows are Form 4 filings for this issuer from SEC EDGAR; congressional rows are periodic transaction reports parsed from the House Clerk and the Senate eFD. Values use the reported price for Form 4 and the disclosed range for Congress. See methodology and corrections.
Not investment advice. Disclosures are shown as filed and may lag the trade or be amended. No recommendation is made or implied.